<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00523393</url>
  </required_header>
  <id_info>
    <org_study_id>2006-006573-24</org_study_id>
    <nct_id>NCT00523393</nct_id>
  </id_info>
  <brief_title>Prospective Influence of Bedtime Insulin Glargine on Mobilization and Function of Endothelial Progenitor Cells</brief_title>
  <official_title>Prospective Influence of Bedtime Insulin Glargine on Mobilization and Function of Endothelial Progenitor Cells in Patients With Type 2 Diabetes: a Partially Double-Blind, Randomized, Three-Arm Unicenter Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heidelberg University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Heidelberg University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this trial, it will be studied whether early addition of the long acting insulin analogue&#xD;
      Glargine is capable of increasing the number and differentiation of endothelial progenitor&#xD;
      cells (EPC) in patients with type 2 diabetes, which can be seen as a marker of vascular&#xD;
      regenerative potential and cardiovascular risk. In addition, the effect of Glargine on&#xD;
      microvascular function will be studied. This will be done using laser Doppler measurements of&#xD;
      the skin; in addition, MRI of the heart will be performed which is capable of quantifying the&#xD;
      perfusion reserve of the myocardium and additional functional aspects of ventricular&#xD;
      function. A beneficial effect of early addition of bedtime Glargine on EPC and vascular as&#xD;
      well as myocardial function in this study might argue for a change in the therapeutic&#xD;
      approach in type 2 diabetes and possibly improve the cardiovascular outcome in patients&#xD;
      affected.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2007</start_date>
  <completion_date type="Anticipated">May 2010</completion_date>
  <primary_completion_date type="Anticipated">December 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of number of circulating EPC 4 weeks after start of therapy compared to baseline as detected by FACS analysis</measure>
    <time_frame>4 weaks of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of number of circulating EPC 4 as detected by in vitro outgrowth</measure>
    <time_frame>4 weeks, 4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Skin microvascular function (as measured by laser Doppler perfusion upon heat stimulation)</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial function and myocardial perfusion reserve as measured by MRI</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intima-Media-Thickness</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long-term Glucose control (HbA1c)</measure>
    <time_frame>4 weeks, 4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short-term Glucose control (fasting glucose)</measure>
    <time_frame>4 weeks, 4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Markers of inflammation and vascular risk in diabetes</measure>
    <time_frame>4 weeks, 4 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin Glargin</intervention_name>
    <description>Titration of bedtime insulin glargin aiming at normal morning fasting glucose</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Lantus®, HOE901 (internal code number Sanofi-Aventis)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Human Insulin</intervention_name>
    <description>Titration of bedtime human insulin aiming at normal morning fasting glucose</description>
    <arm_group_label>3</arm_group_label>
    <other_name>Insuman Basal®, HR1799(internal code number Sanofi-Aventis)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Type 2 Diabetes&#xD;
&#xD;
          -  Oral antidiabetic therapy&#xD;
&#xD;
          -  Age 35 - 70&#xD;
&#xD;
          -  6,5%&lt; HbA1c ≤ 9%&#xD;
&#xD;
          -  Ability of subject to understand character and individual consequences of clinical&#xD;
             trial&#xD;
&#xD;
          -  Written informed consent must be available before enrollment in the trial&#xD;
&#xD;
          -  For women with childbearing potential, adequate contraception (Pearl Index &lt; 1%, e.g.&#xD;
             birth control pill) and negative blood pregnancy test&#xD;
&#xD;
          -  6,5%&lt; HbA1c ≤ 9%&#xD;
&#xD;
          -  Ability of subject to understand character and individual consequences of clinical&#xD;
             trial&#xD;
&#xD;
          -  Written informed consent must be available before enrollment in the trial&#xD;
&#xD;
          -  For women with childbearing potential, adequate contraception (Pearl Index &lt; 1%, e.g.&#xD;
             birth control pill) and negative blood pregnancy test&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  MODY&#xD;
&#xD;
          -  Malignant disease&#xD;
&#xD;
          -  Hematopoietic disorders&#xD;
&#xD;
          -  Impairment of renal function (Serum creatinine &gt; 1,5mg/dl)&#xD;
&#xD;
          -  autoimmune disease&#xD;
&#xD;
          -  treatment with immunosuppressive drugs&#xD;
&#xD;
          -  Psychiatric disease&#xD;
&#xD;
          -  Myocardial ischemia during previous 6 month&#xD;
&#xD;
          -  Acute coronary syndrome&#xD;
&#xD;
          -  pAVK IIb, III, IV (Fontaine-Ratschow)&#xD;
&#xD;
          -  Erythropoietin treatment&#xD;
&#xD;
          -  Glitazone treatment during two weeks before inclusion&#xD;
&#xD;
          -  Insulin treatment during two weeks before inclusion&#xD;
&#xD;
          -  Pregnancy and lactation&#xD;
&#xD;
          -  History of hypersensitivity to the investigational product or to any drug with similar&#xD;
             chemical structure or to any excipient present in the pharmaceutical form of the&#xD;
             investigational product&#xD;
&#xD;
          -  Participation in other clinical trials and observation period of competing trials,&#xD;
             respectively&#xD;
&#xD;
          -  No subject will be allowed to enroll in this trial more than once.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Per M Humpert, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Heidelberg, Dept. Medicine 1, Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Per M Humpert, Dr.</last_name>
    <phone>+49 6221 56</phone>
    <phone_ext>8027</phone_ext>
    <email>per.humpert@med.uni-heidelberg.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dimitrios Oikonomou</last_name>
    <phone>+49 6221 56</phone>
    <phone_ext>37944</phone_ext>
    <email>dimitrios.oikonomou@med.uni-heidelberg.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Clinics Heidelberg, Dept. Medicine1</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dimitrios Oikonomou</last_name>
      <phone>+49 6221 56</phone>
      <phone_ext>37944</phone_ext>
      <email>dimitrios.oikonomou@med.uni-heidelberg.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2009</verification_date>
  <study_first_submitted>August 29, 2007</study_first_submitted>
  <study_first_submitted_qc>August 29, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2007</study_first_posted>
  <last_update_submitted>February 12, 2009</last_update_submitted>
  <last_update_submitted_qc>February 12, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 13, 2009</last_update_posted>
  <responsible_party>
    <name_title>Dr. Per M. Humpert</name_title>
    <organization>University of Heidelberg</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin, Globin Zinc</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

